
BIBLIOGRAFÍA RECOMENDADA

“Expansión del tratamiento antirretroviral en entornos con recursos limitados: Directrices para un enfoque de salud pública, resumen de Orientación April 2002” y “Scaling up Antiretroviral Therapy in Resource Limited Settings: Guidelines for a Public Health Approach, World Health Organization, abril 2002”. En: http://www.who.int/HIV_AIDS

DHHS Panel on Clinical Practices for the treatment of HIV infection: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC February 2001. En: <http://www.hivatis.org>.

Pozniak A, Gazzard B, Churchill D, on behalf of the BHIVA Executive Committee. British HIV association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. Londres, enero 2000. En: <http://www.aidsmap.com>

Rubio R, Berenguer J, Miró J, et al. Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. *Enferm Infecc Microbiol Clin.* 2002, 20(6): 244-301.

Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults. Updated recommendations of the IAS-USA Panel. *JAMA.* 2000, 283: 381-390.

Bartlett, J. *Abbreviated Guide to Medical Management of HIV Infection 2000-2001.* Johns Hopkins University School of Medicine

Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. *N Engl J Med.* 1996; 334: 701-706.

O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+lymphocyte counts and the risk of progression to AIDS. *N Engl J Med.* 1996; 334: 426-43 I.

Mellors J, Muñoz AM, Giorgi JV. Plasma viral load and CD4 +lymphocytes prognostic markers of HIV-1 infection. *Ann Intern Med.* 1997; 126: 946-954

Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. *AIDS.* 1997; 11 (12): F101-105.

Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. *N Eng J Med.* 1997; 336: 1531-1532.

Sepkowitz KA. Effect of HAART on natural history of AIDS-related opportunistic disorders. *Lancet.* 1998; 35 1: 228-230.

Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Eng J Med.* 1998; 338: 853-860.

Staszewski S, Morales-Ramirez J, Tashima TK, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. *N Engl J Med.* 1999; 341: 1865-1 873.

Eron JJ, Yetzer ES, Ruane PJ, et al. Efficacy, safety and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. *AIDS.* 2000; 14: 67 1-68 1.

Tashima K, Staszewski S, Morales-Ramirez JO et al. Continued viral suppression in patients treated with efavirenz (EFV)+zidovudine (ZDV)+lamivudine (3TC) at 112 weeks: Kaplan-Meier analysis for the extended cohort of study 006. 10th European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden 28-31 May, 2000. Abstract WeP252. *Clin Microbial Infect.* 2000; 6 (suppl. 1): 139.

Bonfanti P, Valsecchi L, Parazzini F et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. *J Acquir Immune Defic Syndr Hum Retrovirol.* 2000; 23: 236-245.

Considerations for TB therapy for HIV-infected patients treated with antiretroviral agents. JAMA HIV/AIDS Resource Center: <http://www.ama-assn.org>.

Centers for Disease Control and Prevention. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. *MMWR Morb Mortal Wkly Rep.* 2000; 49: 185-189.

Ledergerber B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. *JAMA.* 1999; 282: 2220-2226.

Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS Caps. From: 6th Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, Ill. Abstract 92.

El Grupo de Estudio de Sida de la SEIMC, la Sociedad Española de Farmacia Hospitalaria y la Secretaria del Plan National sobre el Sida. Recomendaciones para mejorar la adherencia al tratamiento antirretroviral. Ministerio de Sanidad y Consumo. 1999.

Comisión Asesora del Plan National sobre el SIDA. Resistencia a los fármacos antirretrovirales. Ministerio de Sanidad y Consumo, Madrid, Octubre de 1997.

Hirsch M, Brun-Vézinet F, D'Aquila R, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. *JAMA.* 2000; 283: 2417-2426.

Anónimo: Guidelines for the performance of CD4+T-cell determinations in persons with human immunodeficiency virus infection. *MMWR Morb Mortal Wkly Rep.* 1992; 4 1: 1-19.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper D. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. *Lancet.* 1999; 353: 2093-2099.

Piscitelli S. Effect of heat on efficacy on antiretrovirals? December, 1999. In: <http://www.medscape.org>.

Tuset M, Mire JM, Codina CJ. Interacciones medicamentosas de interés en la terapia del VIH. Gonzalez J, Moreno S, Rubio R (Eds). Infección por VM 1998. 1a. Edición. Ediciones Doyma SA. Barcelona. 1998: 281-296.

Fuertes A, Otero MJ. Interacciones de los fármacos antirretrovirales. Med Clin (Barc). 1999; 113: 94-102.

